Bibliography
Found 365 results
Filters: Keyword is Internal [Clear All Filters]
Socioeconomic Status and Neuropsychological Functioning: Associations in an Ethnically Diverse HIV+ Cohort. Clin Neuropsychol. 2015 ;29(2):232-54.
. Aging and HIV/AIDS: neurocognitive implications for older HIV-positive Latina/o adults. Behav Med. 2014 ;40(3):116-23.
. Brain morphometric correlates of metabolic variables in HIV: the CHARTER study. J Neurovirol. 2014 ;20(6):603-11.
CCR2 on CD14(+)CD16(+) monocytes is a biomarker of HIV-associated neurocognitive disorders. Neurol Neuroimmunol Neuroinflamm [Internet]. 2014 ;1(3):e36. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25340088
. Characterizing HIV medication adherence for virologic success among individuals living with HIV/AIDS: Experience with the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) cohort. J HIV AIDS Soc Serv. 2014 ;13(1):8-25.
. Cytokine secretion from brain macrophages infected with human immunodeficiency virus in vitro and treated with raltegravir. BMC Infect Dis. 2014 ;14:386.
. Effects of information processing speed on learning, memory, and executive functioning in people living with HIV/AIDS. J Clin Exp Neuropsychol. 2014 ;36(8):806-17.
. Epigenetic alterations in the brain associated with HIV-1 infection and methamphetamine dependence. PLoS One. 2014 ;9(7):e102555.
. Evidence of the innate antiviral and neuroprotective properties of progranulin. PLoS One. 2014 ;9(5):e98184.
. Genetic variation in iron metabolism is associated with neuropathic pain and pain severity in HIV-infected patients on antiretroviral therapy. PLoS One. 2014 ;9(8):e103123.
HCV, but not HIV, is a risk factor for cerebral small vessel disease. Neurol Neuroimmunol Neuroinflamm. 2014 ;1(3):e27.
. Heme oxygenase-1 deficiency accompanies neuropathogenesis of HIV-associated neurocognitive disorders. J Clin Invest. 2014 ;124(10):4459-72.
. HIV protease inhibitor exposure predicts cerebral small vessel disease. AIDS. 2014 ;28(9):1297-306.
HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter. J Neurovirol. 2014 ;20(3):209-18.
The impact of neurobehavioral features on medication adherence in HIV: evidence from longitudinal models. AIDS Care. 2014 ;26(1):79-86.
. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis. 2014 ;59(7):1032-7.
. Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders. Curr HIV Res. 2014 ;12(2):85-96.
. Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders. Br J Pharmacol. 2014 ;171(24):5757-73.
The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings. Clin Biochem. 2014 ;47(4-5):258-66.
. The role of decision-making ability in HIV/AIDS: impact on prospective memory. J Clin Exp Neuropsychol. 2014 ;36(7):730-41.
. A Smartphone App to Screen for HIV-Related Neurocognitive Impairment. J Mob Technol Med. 2014 ;3(1):23-26.
. A Smartphone App to Screen for HIV-Related Neurocognitive Impairment. Journal of Mobile Technology in Medicine [Internet]. 2014 ;3(1):23-26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24860624
. The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment. J Acquir Immune Defic Syndr. 2014 ;65(2):190-7.
. Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol. 2013 ;19(2):150-6.
A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals. J Neuroimmune Pharmacol. 2013 ;8(5):1123-35.
.